A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats
www.influenzajournal.com, Published Online 10 April 2013
Respiratory syncytial virus (RSV) has been recognized as an important vaccine target for over 60 years; however, there is no vaccine on the market today. A clinical trial conducted in the 1960s evaluated a formalin-inactivated, alum-absorbed RSV preparation (FI-RSV) as a possible vaccine candidate.1 Infants vaccinated with FI-RSV who subsequently acquired a natural infection, developed enhanced respiratory disease (ERD), especially in the youngest group of vaccinees who were na€ıve to RSV prior to vaccination, which led to the death of two of these children.
| Media Name | Media Type | Description | Download |
|---|---|---|---|
| A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats | Download |